267 related articles for article (PubMed ID: 35117304)
1. The use of real-world data for clinical investigation of effectiveness in drug development.
Wang P; Chow SC
J Biopharm Stat; 2024 Mar; ():1-24. PubMed ID: 38519266
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Effectiveness: Bridging the Gap Between Clinical Trials and Real-world Practice.
Nguyen DD; Satkunasivam R; Wallis CJD
Eur Urol Oncol; 2024 Feb; 7(1):25-26. PubMed ID: 37479643
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis.
Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
Lancet Reg Health West Pac; 2023 Sep; 38():100841. PubMed ID: 37457900
[TBL] [Abstract][Full Text] [Related]
4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.
Yoshino T; Cervantes A; Bando H; Martinelli E; Oki E; Xu RH; Mulansari NA; Govind Babu K; Lee MA; Tan CK; Cornelio G; Chong DQ; Chen LT; Tanasanvimon S; Prasongsook N; Yeh KH; Chua C; Sacdalan MD; Sow Jenson WJ; Kim ST; Chacko RT; Syaiful RA; Zhang SZ; Curigliano G; Mishima S; Nakamura Y; Ebi H; Sunakawa Y; Takahashi M; Baba E; Peters S; Ishioka C; Pentheroudakis G
ESMO Open; 2023 Jun; 8(3):101558. PubMed ID: 37236086
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
Takahashi S; Ouchi K; Sakamoto Y; Mori T; Shimodaira H; Takahashi M; Ohori H; Kudo C; Takahashi Y; Imai H; Akiyama S; Takahashi M; Suto T; Murakawa Y; Oishi T; Isobe H; Okada Y; Kawai S; Yoshioka T; Sato T; Shindo Y; Sugiyama S; Komine K; Chiba N; Okita A; Yamaguchi T; Ishioka C
J Gastrointest Oncol; 2023 Apr; 14(2):676-691. PubMed ID: 37201044
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer.
Yip PL; Fung WHB; Lee FAS; Lee CF; Wong NSM; Lee SF
Front Oncol; 2023; 13():1138357. PubMed ID: 37091154
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.
Souza KM; Carrasco G; Rojas-Cortés R; Michel Barbosa M; Bambirra EHF; Castro JL; Alvares-Teodoro J
PLoS One; 2023; 18(10):e0284006. PubMed ID: 37824507
[TBL] [Abstract][Full Text] [Related]
9. Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Lanade O; Geynisman DM
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230530
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?
Katona L; Bitter I; Czobor P
Transl Psychiatry; 2021 Oct; 11(1):510. PubMed ID: 34615850
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter aortic valve implantation versus surgical aortic valve replacement for treatment of severe aortic stenosis: comparison of results from randomized controlled trials and real-world data.
Wang D; Huang L; Zhang Y; Cheng Z; Zhang X; Ren P; Hong Q; Kang D
Braz J Cardiovasc Surg; 2020 Jun; 35(3):346-367. PubMed ID: 32549107
[TBL] [Abstract][Full Text] [Related]
12. Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis.
Zhang X; Fu S; Meng R; Ren Y; Shang Y; Tian L
Transl Cancer Res; 2020 Nov; 9(11):6963-6987. PubMed ID: 35117304
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.
Khanani AM; Constantine RN; Blot KH; Lescrauwaet B; Szurman P
Acta Ophthalmol; 2021 Sep; 99(6):e823-e836. PubMed ID: 33369248
[TBL] [Abstract][Full Text] [Related]
14. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
15. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
